Show simple item record

dc.contributor.authorLim, SLen_US
dc.contributor.authorSmith, Pen_US
dc.contributor.authorSyed, Nen_US
dc.contributor.authorCoens, Cen_US
dc.contributor.authorWong, Hen_US
dc.contributor.authorvan der Burg, Men_US
dc.contributor.authorSzlosarek, Pen_US
dc.contributor.authorCrook, Ten_US
dc.contributor.authorGreen, JAen_US
dc.date.accessioned2018-08-30T13:39:31Z
dc.date.issued2008-04-22en_US
dc.identifier8en_US
dc.identifier.citationBRITISH JOURNAL OF CANCER, 2008, 98 pp. 1452 - 1456en_US
dc.identifier.issn0007-0920en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2426
dc.identifier.eissn1532-1827en_US
dc.identifier.doi10.1038/sj.bjc.6604325en_US
dc.description.abstractThe Fanconi gene family has a role in DNA repair and inactivation of FANCF has been proposed as a mechanism of sensitisation to platinum chemotherapy. This study sought to confirm this hypothesis in cell lines and a large series of ovarian cancer samples. Promoter methylation was assessed by methylation-sensitive polymerase chain reaction of FANCF in nine ovarian cancer cell lines and 74 ovarian cancer samples taken from patients entered on a trial of cisplatin-based chemotherapy. This study confirmed methylation-dependent silencing of FANCF in one out of nine ovarian cancer cell lines. Methylation of FANCF was demonstrated in 13.2% of 53 evaluable ovarian tumour samples. Progression-free survival gave an HR of 3.63 ( 95% CI: 1.54 - 8.54, P = 0.0016) in favour of the unmethylated cases. There was no association with overall survival. This study does not support methylation-dependent silencing of FANCF as a mechanism of sensitisation to platinum-based chemotherapy in ovarian cancer.en_US
dc.format.extent1452 - 1456en_US
dc.languageEnglishen_US
dc.language.isoEnglishen_US
dc.publisherNATURE PUBLISHING GROUPen_US
dc.titlePromoter hypermethylation of FANCF and outcome in advanced ovarian canceren_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1038/sj.bjc.6604325en_US
rioxxterms.licenseref.startdate2008-04-22en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfBRITISH JOURNAL OF CANCERen_US
pubs.notesaffiliation: Green, JA (Reprint Author), Univ Liverpool, Sch Canc Studies, Div Surg & Oncol, Liverpool L7 8XP, Merseyside, England. Lim, S. L.; Green, J. A., Univ Liverpool, Sch Canc Studies, Div Surg & Oncol, Liverpool L7 8XP, Merseyside, England. Lim, S. L.; Smith, P.; Syed, N.; Crook, T., Breakthrough Toby Robins Breast Canc Res Ctr, Inst Canc Res, Chester Beatty Labs, London, England. Coens, C., EORTC Data Ctr, Brussels, Belgium. Wong, H., Clatterbridge Ctr Oncol NHS Trust, Wirral, Merseyside, England. van der Burg, M., Erasmus Univ, Med Ctr, Rotterdam, Netherlands. Szlosarek, P., Univ London St Bartholomews Hosp Med Coll, Dept Med Oncol, Lung & Mesothelioma Unit, London, England. keywords: ovarian cancer; Fanconi genes; platinum resistance; clinical trial keywords-plus: ANEMIA-BRCA PATHWAY; CISPLATIN; SURVIVAL; METHYLATION; CELL; DISRUPTION; TUMORS; DNA research-areas: Oncology web-of-science-categories: Oncology author-email: J.A.Green@liverpool.ac.uk number-of-cited-references: 17 times-cited: 34 usage-count-last-180-days: 0 usage-count-since-2013: 3 journal-iso: Br. J. Cancer doc-delivery-number: 288SU unique-id: ISI:000255006900021 oa: gold_or_bronze da: 2018-08-30en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.volume98en_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorCrook, Timothyen_US
dc.contributor.icrauthorSyed, Neloferen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record